Taking Longer Than Expected: QRxPharma’s MoxDuo Gets “Complete Response” As Firm Works On Data
This article was originally published in The Pink Sheet Daily
Executive Summary
QRxPharma needs more time to complete a quality control report validating 30 million data points related to the marketing application for combination opioid analgesic MoxDuo. Faced with perplexed investors, CEO explains that a delay related to submitting the report is behind the latest “complete response” letter from FDA.